[PDF][PDF] Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
AC Huang, N Mehta, JL Dodge, FY Yao… - Hepatology, 2018 - Wiley Online Library
Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study
Background & Aims There is controversy over the effects of direct-acting antiviral (DAA)
therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) …
therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) …
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts
A The - Journal of Hepatology, 2016 - Elsevier
Background & Aims Sustained virological response following interferon-based antiviral
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …
[PDF][PDF] Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma
S Pol - J Hepatol, 2016 - natap.org
Background and aims: Sustained virological response following antiviral interferon-based
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …
treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular …
[PDF][PDF] Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct …
A Zanetto, S Shalaby, A Vitale, C Mescoli… - Liver …, 2017 - Wiley Online Library
Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following
direct‐acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete …
direct‐acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete …
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …
[HTML][HTML] No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
SM Rutledge, H Zheng, DK Li, RT Chung - Hepatoma research, 2019 - ncbi.nlm.nih.gov
Aim: Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC) in the
United States. Achieving sustained viral response with interferon (IFN) treatment reduces the …
United States. Achieving sustained viral response with interferon (IFN) treatment reduces the …
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma
JD Yang, BA Aqel, S Pungpapong… - Journal of …, 2016 - journal-of-hepatology.eu
We read with great interest the article by Reig et al., published in the Journal of Hepatology,
which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular …
which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular …
Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents
F Kanwal, J Kramer, SM Asch, M Chayanupatkul… - Gastroenterology, 2017 - Elsevier
Background and Aims The risk of hepatocellular cancer (HCC) after sustained virological
response (SVR) with direct-acting antivirals (DAA) is unclear. Our aim was to examine the …
response (SVR) with direct-acting antivirals (DAA) is unclear. Our aim was to examine the …
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment
HA Torres, JN Vauthey, MP Economides… - Journal of …, 2016 - journal-of-hepatology.eu
We read with interest the article by Reig et al.[1] and applaud their pharmacovigilance
efforts. However, because we work in a major cancer center in the United States, we are …
efforts. However, because we work in a major cancer center in the United States, we are …
相关搜索
- acting antivirals liver transplant
- hepatocellular carcinoma liver transplantation
- waitlist dropout regional therapy
- acting antivirals waitlist dropout
- acting antivirals regional therapy
- waitlist dropout carcinoma recurrence
- acting antivirals carcinoma recurrence
- waitlist dropout liver transplant
- carcinoma recurrence regional therapy
- liver transplant regional therapy
- carcinoma recurrence liver transplant
- hepatocellular carcinoma antiviral therapy
- hepatocellular carcinoma tumor recurrence
- dropout rate carcinoma progression
- acting antivirals infected patients
- liver transplant infected patients